Clinical Laboratory Tests 2 in Extremely Low Birth Weight (ELBW) Infants Exposed to Furosemide or Bumetanide in the Neonatal Intensive Care Unit

Clinical Laboratory Tests 2 data
Study Description
This was a retrospective observational chart review to determine the incidence of events of special interest for hospitalized, extremely low birth weight infants admitted to one of two neonatal intensive care units and exposed to furosemide or bumetanide. The trial enrolled 679 infants, with 521 receiving furosemide treatment; 166 of these infants received bumetanide in addition to furosemide (no infants received bumetanide only). There were profound dosing differences between the two sites. Infants administered furosemide tended to be sicker than infants not administered furosemide at both sites. No association between diuretic use and death was found. Increased drug exposure was associated with higher rates of bronchopulmonary dysplasia diagnosis. Rates of hearing loss, cerebral palsy diagnosis, and abnormal Bayley scores were low (<15%) at each site. Rates of both hearing loss and kidney stones differed between sites. Chart review of extremely low birth weight infants admitted to the neonatal intensive care units at two sites.

临床实验室检验数据集2
研究描述
本研究为回顾性观察性病历审查研究，旨在明确入住两家新生儿重症监护病房（Neonatal Intensive Care Unit, NICU）、接受呋塞米（furosemide）或布美他尼（bumetanide）治疗的住院超低出生体重儿的特定关注事件发生率。本研究共纳入679名婴儿，其中521名接受呋塞米治疗；该521名婴儿中有166名除呋塞米外还额外接受了布美他尼治疗，无婴儿仅接受布美他尼治疗。两家机构间存在显著的给药剂量差异。两家机构中，接受呋塞米治疗的婴儿病情均较未接受该治疗的婴儿更危重。未发现利尿剂使用与死亡之间存在关联。药物暴露量增加与支气管肺发育不良（Bronchopulmonary Dysplasia, BPD）诊断率升高相关。各机构的听力损失、脑瘫诊断及异常贝利评分（Bayley Score）发生率均低于15%。两家机构的听力损失与肾结石发生率均存在差异。本研究针对入住两家新生儿重症监护病房的超低出生体重儿开展病历审查。